Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences

NEXT STORY
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
PREV STORY
Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to Optimize Cancer Immunotherapy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial

NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced ...

author_avatar
NASDAQ Market News

Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Immune Design ...

author_avatar
NASDAQ Market News

Asterias Biotherapeutics to Report Second Quarter Results on August 14, 2017

FREMONT, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a ...

author_avatar
NASDAQ Market News